To assess the ability of fisetin to alter the expression of these transcription factors, we examined Foxp3 and RORγt expression in ACD model mice, revealing that such treatment reduced decreased RORγt expression and enhanced Foxp3 expression. The gene discussed is FOXP3; the disease is granular corneal dystrophy type II.